摘要:
The present invention relates to a thiazole derivative represented by formula (I) wherein Ar 1 represents a substituted or unsubstituted phenyl or thienyl group, Y 1 and Y 2 are different and each represents a nitrogen atom or a sulfur atom, R 1 represents a hydrogen atom, a C 1 to C 5 alkyl group, a phenyl group, or an amino group unsubstituted or mono- or di-substituted with a C 1 to C 5 alkyl group, and R 2 represents a substituted or unsubstituted nitrogen heterocycle group, or a pharmaceutically acceptable salt thereof. The compound of the present invention are a dopamine D 4 receptor antagonist which has an antipsychotic effect without causing any extrapyramidal disorder.
摘要:
This invention provides a 2-carbonylthiazole derivative represented by formula (I): [wherein each of Ar 1 and Ar 2 represents a phenyl group, a phenyl group having one or two substituents selected from "a halogen atom, an alkyl group having 1 to 5 carbon atoms, a trifluoromethyl group, an alkoxy group having 1 to 5 carbon atoms and a hydroxyl group" or a thienyl group; R 1 represents an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group or an amino group represented by formula N(R 3 )R 4 (wherein each of R 3 and R 4 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, or R 3 and R 4 , together with the nitrogen atom to which they are bound, form a pyrrolidino, piperidino, morpholino or piperazino group, or a pyrrolidino, piperidino, morpholino or piperazino group having one to four substituents selected from "an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms and a hydroxyl group"); Y 1 -Y 2 represents CH-CO or C=C(R 2 ) (wherein R 2 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms); and n is an integer of from 1 to 4] or a pharmaceutically acceptable salt thereof. It also provides a medicament which comprises the 2-carbonylthiazole derivative of formula (I) or a pharmaceutically acceptable salt thereof and a dopamine D 4 receptor antagonist which contains the same as the active ingredient, which are useful as drugs for preventing and treating dopamine D 4 receptor-related morbid states such as schizophrenia and problematic behavior caused by cerebrovascular accidents and senile dementia, and also as the drugs which do not induce extrapyramidal disorders as side effects.
摘要:
2-Carbonylthiazole derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof (wherein Ar?1 and Ar2¿ represent each phenyl optionally having one or two substituents selected from among halogeno, C¿1-5? alkyl, trifluoromethyl, C1-5 alkoxy and hydroxy or thienyl; R?1¿ represents C¿1-5? alkoxy, hydroxy or amino represented by the formula N(R?3)R4¿ (wherein R?3 and R4¿ represent each hydrogen or C¿1-5? alkyl, or R?3 and R4¿ together with the nitrogen atom to which they are bonded may form pyrrolidino, piperidino, morphorino or piperazino optionally having one to four substituents selected from among C¿1-5? alkyl, C1-5 alkoxy and hydroxy); Y?1-Y2¿ represents CH-CO or C=C(R2) (wherein R2 represents hydrogen or C¿1-5? alkyl); and n is an integer of 1 to 4); drugs comprising the derivatives represented by the above general formula (I) or pharmaceutically acceptable salts thereof; and dopamine D4 receptor antagonists containing as the active ingredient the same. These drugs are useful as preventives and remedies for various diseases in which dopamine D4 receptors participate, for example, schizophrenia, cerebrovascular disorders and problematic behaviors accompanying senile dementia without showing any extrapyramidal disorders as the side effect.
摘要:
A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X 3 and X 4 are the same or different, and are each a hydrogen atom, a halogen atom, a C 1-5 alkyl group, a C 1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R 1 and R 2 are the same or different, and are each a hydrogen atom, a C 1-10 alkyl group, a C 3-15 alkoxyalkyl group or a C 3-15 alkylaminoalkyl group, or R 1 and R 2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X 1 and X 2 are the same or different, and are each a hydrogen atom, a C 1-5 alkyl group, a C 1-5 alkoxy group or a halogen atom, or X 1 and X 2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.
摘要:
A process for producing a 3-alkoxy-2-amino-6-fluoro bicyclo [3.1.0] hexane-2, 6-dicarboxylic acid derivative represented by the formula (I) or a salt thereof, which includes converting a compound represented by the formula (VI) or a salt thereof to the compound represented by the formula (I) or a salt thereof.
摘要:
1,2-Dihydro-2-oxoquinoline derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, wherein Ar represents pyridyl or group represented by general formula (II) (wherein X?3 and X4¿ are the same or different and each represents hydrogen, halogeno, C¿1-5? alkyl, C1-5 alkoxy, hydroxy, or trifluoromethyl); Y represents nitrogen, CH, or C(OH); R?1 and R2¿ are the same or different and each represents hydrogen, C¿1-10? alkyl, C3-15 alkoxyalkyl, or C3-15 alkylaminoalkyl or R?1 and R2¿ form a cycloamino group together with the adjacent nitrogen atom; X?1 and X2¿ are the same or different and each represents hydrogen, C¿1-5? alkyl, C1-5 alkoxy, or halogeno or X?1 and X2¿ together represent alkylenedioxy; and n is an integer of 1 to 3.
摘要:
A process for producing a 2-oxobicyclo[3.1.0]hex-3-ene-6-carboxylic acid derivative represented by a formula: (wherein R 1 represents a hydrogen atom, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 3-6 cycloalkyl C 1-6 alkyl group, a C 1-6 alkyl group substituted with a substituted or unsubstituted phenyl group, a C 1-6 alkoxy C 1-6 alkyl group, a C 1-6 hydroxyalkyl group, a C 1-6 alkylthio C 1-6 alkyl group, a C 1-6 mercaptoalkyl group, or a substituted or unsubstituted phenyl group) characterized by reacting a 4-hydroxy-2-oxobicyclo[3.1.0]hexane-6-carboxylic acid derivative represented by a formula: (wherein R 1 has the same meaning as described above, and R 2 represents a hydrogen atom or a protective group of a hydroxyl group) in the presence of an acid or a base. A process for producing the compounds which are useful for efficient syntheses of 2-amino-3-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acids is provided.
摘要翻译:一种制备下式代表的2-氧代双环[3.1.0]己-3-烯-6-羧酸衍生物的方法:(其中R1代表氢原子,C1-6烷基,C3-6环烷基 ,C3-6环烷基C1-6烷基,被取代或未取代的苯基取代的C1-6烷基,C1-6烷氧基C1-6烷基,C1-6羟烷基,C1-6烷硫基 C 1-6烷基,C 1-6巯基烷基或取代或未取代的苯基),其特征在于使由下式表示的4-羟基-2-氧代双环[3.1.0]己烷-6-羧酸衍生物 其中R1具有与上述相同的含义,并且R2表示氢原子或羟基的保护基团)在酸或碱存在下反应。 提供了用于有效合成2-氨基-3-氟二环[3.1.0]己烷-2,6-二羧酸的化合物的制备方法。
摘要:
Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC 4 receptor antagonistic effect.
摘要:
Carbamoyl tetrahydropyridine derivatives represented by general formula (1) and being efficacious against CRF-related diseases; medicinally acceptable salts of the same; and intermediates for the preparation thereof, wherein R?1 and R2¿ are each independently hydrogen, C¿1?-C5 alkyl, or the like; Y?1-Y2 is (R4)C=C(R5), (R6¿)C=N, N=N, (R7)N-CO, or N=C(R?8); X1, X2 and X3¿ are each independently hydrogen, halogeno, or the like; R?3, R4, R5 and R6¿ are each independently hydrogen or alkyl; R7 is hydrogen, C¿1?-C5 alkyl, or the like; and R?8¿ is hydrogen or carbamoyl.
摘要:
Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R 1 and R 2 are identical or different, and each represents a hydrogen atom, a C 1 -C 5 alkyl group, or the like; Y 1 -Y 2 represents (R 4 )C=C(R 5 ), (R 6 )C=N, N=N, (R 7 )N-CO, or N=C(R 8 ); X 1 , X 2 , and X 3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R 3 , R 4 , R 5 , and R 6 are identical or different, and each represents a hydrogen atom or an alkyl group; R 7 represents a hydrogen atom, a C 1 -C 5 alkyl group, or the like; and R 8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.